Get the Stockscreener App
0.2294
2.51%
-0.0059
After Hours:
.24
0.0106
+4.62%
Processa Pharmaceuticals Inc stock is traded at $0.2294, with a volume of 584.29K.
It is down -2.51% in the last 24 hours and down -41.03% over the past month.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
See More
Previous Close:
$0.2353
Open:
$0.23
24h Volume:
584.29K
Relative Volume:
0.30
Market Cap:
$1.16M
Revenue:
-
Net Income/Loss:
$-11.53M
P/E Ratio:
-0.0476
EPS:
-4.82
Net Cash Flow:
$-11.12M
1W Performance:
+3.99%
1M Performance:
-41.03%
6M Performance:
-83.01%
1Y Performance:
-89.08%
1-Day Range:
$0.22
$0.2399
1-Week Range:
$0.2039
$0.25
52-Week Range:
$0.15
$3.10
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
7380 COCA COLA DRIVE, HANOVER
Compare PCSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.2294 | 1.16M | 0 | -11.53M | -11.12M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 126.09B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 64.01B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
629.51 | 36.63B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.64B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.77 | 27.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Processa Pharmaceuticals Inc [PCSA] Shares Rise 8.43 % on Wednesday - knoxdaily.com
Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN
Processa Pharmaceuticals Inc (PCSA) can make a big difference with a little luck - Sete News
A Closer Look at Processa Pharmaceuticals Inc (PCSA) Stock Gains - investchronicle.com
Recent Insider Activity Suggests Potential Gains for Processa Pharmaceuticals Inc (PCSA) - knoxdaily.com
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025 - GlobeNewswire
FDA Project Optimus: Processa Unveils New Approach for Rare Disease Treatment Success - Stock Titan
Data-Based Insights About Processa Pharmaceuticals Inc (PCSA) - stocksregister.com
Processa Pharmaceuticals stock hits 52-week low at $0.22 - Investing.com
PCSA Stock Sees Decline of Approximately -11.67% in Last Five Days - knoxdaily.com
Processa Pharmaceuticals stock hits 52-week low at $0.36 - Investing.com
Processa Pharmaceuticals stock hits 52-week low at $0.36 By Investing.com - Investing.com India
Processa Pharmaceuticals (PCSA) to Release Quarterly Earnings on Friday - Defense World
Processa Pharmaceuticals stock hits 52-week low at $0.4 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals stock hits 52-week low at $0.4 - Investing.com
Processa Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Processa Pharmaceuticals (PCSA) to Release Quarterly Earnings on Thursday - Defense World
Processa Pharmaceuticals Inc. (PCSA) reports earnings - qz.com
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference - The Manila Times
Cancer Therapy Innovator Processa Pharmaceuticals Opens Door to Investors at Elite MedInvest Conference - StockTitan
Processa Pharmaceuticals stock hits 52-week low at $0.43 By Investing.com - Investing.com Australia
Processa Pharmaceuticals stock hits 52-week low at $0.43 - Investing.com India
Ulcerated Necrobiosis Lipoidica Market to Expand Significantly by 2034, States DelveInsight Reports | Processa Pharmaceuticals - Barchart
Processa Pharmaceuticals stock hits 52-week low at $0.46 - Investing.com
Processa Pharma Stock Price, Quotes and Forecasts - Benzinga
The Insider Secrets to Processa Pharmaceuticals: A Dark Horse in the Race - Elblog.pl
Hidden Gems: Why Insiders Are Banking on Processa Pharmaceuticals - Bit Perfect Solutions
Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
10 Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Processa Pharmaceuticals faces Nasdaq delisting risk over share price By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (NASDAQ:PCSA) Publishes Investor Presentation - Defense World
Processa Pharmaceuticals faces Nasdaq delisting risk over share price - Investing.com
Processa Pharmaceuticals IncOn Feb 4, Received Nasdaq Notice For Bid Price Non-Compliance - Marketscreener.com
Processa Pharmaceuticals Inc (PCSA) Shares Soar Above 1-Year High - The News Heater
Processa Pharmaceuticals to Present at 2025 BIO CEO & Investor Conference - Nasdaq
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference - GlobeNewswire
Processa Pharma's Cancer Pipeline Takes Center Stage at Elite BIO Investor Conference - StockTitan
Gastroparesis Market Expected to rise, 2034 | Vanda - openPR
Financial Analysis: Processa Pharmaceuticals Inc (PCSA)’s Ratios Unveil Key Insights - The Dwinnex
Processa Pharmaceuticals CEO George Ng buys shares worth $69,542 - MSN
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Processa Pharmaceuticals Raises $5M in Public Offering - TipRanks
Processa CEO Doubles Down: Purchases Shares at 30% Premium in $5M Strategic Raise - StockTitan
Processa Pharmaceuticals director David Young buys $99,288 in stock - Investing.com India
Processa Pharmaceuticals' chief business officer buys $34,691 in stock - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):